Switch View
© PR Newswire
20.10.2025
ISIN: US0718131099
Baxter International, Inc.
BAX
LISTED
NYSE
BAX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Baxter International, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
NEW YORK, Oct. 20, 2025 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Baxter International, Inc. ("Baxter" or "the Company") (NYSE: BAX) and certain of its officers....
Themefolio
Profiler
Peergroup
© BusinessWire
20.10.2025
ISIN: US0067391062
Addus Homecare Corp
ADUS
LISTED
NASDAQ
Addus HomeCare Announces Third Quarter 2025 Earnings Release and Conference Call
News Preview
Addus HomeCare Corporation (Nasdaq: ADUS), a provider of home care services, announced today that it will release earnings for the third quarter ended September 30, 2025, on Monday, November 3, 2025, after the market close.
Addus HomeCare will host a conference call on Tuesday, November 4, 2025, at 9:00 a.m. Eastern Time. Joining the call from t...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: KY61559X1045
MoonLake Immunotherapeutics
MLTX
LISTED
NASDAQ
MLTX INVESTOR DEADLINE: MoonLake Immunotherapeutics Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
SAN DIEGO, Oct. 20, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that the MoonLake class action lawsuit – captioned Bridgewood v. MoonLake Immunotherapeutics, No. 25-cv-08500 (S.D.N.Y.) – seeks to represent purchasers or acquirers of MoonLake Immunotherapeutics (NASDAQ: MLTX) common stock a...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© PR Newswire
20.10.2025
ISIN: US0043971052
Accuray Inc
ARAY
LISTED
NASDAQ
Accuray Accelerates Transformation Efforts with Appointment of Experienced Executive Leaders to Drive Performance and Growth
News Preview
Industry Veteran Steve La Neve Named Chief Executive Officer
Suzanne Winter to Retire as President and CEO
Company Appoints Steven F. Mayer as Transformation Board Sponsor
Chan W. Galbato Nominated to Board of Directors...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
20.10.2025
ISIN: US4448591028
Humana Inc
HUM
LISTED
NYSE
Humana and Providence Launch Innovative Data Exchange Collaboration to Advance Value-Based Care
News Preview
Humana Inc. (NYSE: HUM) and Providence, a Washington-based health system, today announced a pioneering initiative to streamline and secure data exchange between payers and providers – setting a new standard for interoperability in support of value-based care.
This press release features multimedia. View the full release here: https://www.business...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: US2307701092
Cumberland Pharmaceuticals, Inc.
CPIX
LISTED
NASDAQ
CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO
News Preview
Cumberland to expand its gastroenterology offerings
with the market-leading Helicobacter pylori therapy
NASHVILLE, Tenn., Oct. 20, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focuse...
Themefolio
Profiler
Peergroup
© BusinessWire
20.10.2025
ISIN: US88023B1035
Tempus AI, Inc.
TEM
LISTED
NASDAQ
Ambry Genetics Announces 10-Year Study in Genetics in Medicine Highlighting the Impact of Proactive Exome Reanalysis for Healthcare Equity
News Preview
Ambry Genetics, a leader in genetic testing, and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), announced the publication of a peer-reviewed study in Genetics in Medicine (GIM), the official journal of the American College of Medical Genetics and Genomics (ACMG). The ACMG is a national organization bringing together experts in medical...
Themefolio
Profiler
Peergroup
© Newsfile
20.10.2025
ISIN: CA75339A1012
Rapid Dose Therapeutics Corp.
DOSE
LISTED
CSE
Rapid Dose Therapeutics Releases Nicotine Business Update and Extends Collaboration with International Nicotine Partner
News Preview
Seven-month extension valued at up to approximately $1.8 million CAD supports further evaluation as RDT advances broader commercialization initiatives for NicStrip(TM)Burlington, Ontario--(Newsfile Corp. - October 20, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company"), a Canadian life sciences company developing innovative d...
Themefolio
Profiler
Peergroup
© BusinessWire
20.10.2025
ISIN: US58933Y1055
Merck & Co Inc
MRK
LISTED
NYSE
KEYTRUDA® (pembrolizumab) Demonstrates Long-Term Survival Benefit in Certain Patients With Earlier or Advanced Stages of Non-Small Cell Lung Cancer (NSCLC)
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new long-term data highlighting the sustained survival benefits of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in treating non-small cell lung cancer (NSCLC). The results are based on the exploratory five-year analyses of KEYNOTE-671 evaluating KEYTR...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: US8051111016
Savara Inc
SVRA
LISTED
NASDAQ
Class Action Filed Against Savara Inc. (SVRA) Seeking Recovery for Investors - Contact The Gross Law Firm
News Preview
NEW YORK, Oct. 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Savara Inc. (NASDAQ: SVRA).
Shareholders who purchased...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: US5165441032
Lantheus Holdings Inc
LNTH
LISTED
NASDAQ
Class Action Filed Against Lantheus Holdings, Inc. (LNTH) Seeking Recovery for Investors - Contact The Gross Law Firm
News Preview
NEW YORK, Oct. 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Lantheus Holdings, Inc. (NASDAQ: LNTH).
Shareholders wh...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
Contact The Gross Law Firm by November 17, 2025 Deadline to Join Class Action Against Cytokinetics, Incorporated(CYTK)
News Preview
NEW YORK, Oct. 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cytokinetics, Incorporated (NASDAQ: CYTK).
Shareholders...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
20.10.2025
ISIN: US67079U3068
Nutex Health Inc
NUTX
LISTED
NASDAQ
Shareholders of Nutex Health Inc. Should Contact The Gross Law Firm Before October 21, 2025 to Discuss Your Rights - NUTX
News Preview
NEW YORK, Oct. 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Nutex Health Inc. (NASDAQ: NUTX).
Shareholders who purc...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: US53216B1044
LifeMD, Inc.
LFMD
LISTED
NASDAQ
Shareholders that lost money on LifeMD, Inc.(LFMD) should contact The Gross Law Firm about pending Class Action - LFMD
News Preview
NEW YORK, Oct. 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of LifeMD, Inc. (NASDAQ: LFMD).
Shareholders who purchased...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: US81684M1045
Semler Scientific Inc
SMLR
LISTED
NASDAQ
SMLR LAWSUIT ALERT: The Gross Law Firm Notifies Semler Scientific, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
News Preview
NEW YORK, Oct. 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Semler Scientific, Inc. (NASDAQ: SMLR).
Shareholders wh...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: US0021202025
Atyr Pharma, Inc.
ATYR
LISTED
NASDAQ
Investors who lost money on aTyr Pharma, Inc.(ATYR) should contact The Gross Law Firm about pending Class Action - ATYR
News Preview
NEW YORK, Oct. 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of aTyr Pharma, Inc. (NASDAQ: ATYR).
Shareholders who purc...
Themefolio
Profiler
Peergroup
© BusinessWire
20.10.2025
ISIN: US8523123052
STAAR Surgical Co
STAA
LISTED
NASDAQ
Broadwood Partners Highlights Growing Opposition to STAAR Surgical’s Proposed Sale to Alcon
News Preview
Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today commented on the increasing public opposition to the proposed acquisition of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA) by Alcon Inc. (“Alcon”) (NYSE: ALC). Broadwood continues to urge its fellow shareholders to vote on the GREEN Proxy Card “AGAINST” the...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: US03528H1095
Anixa Biosciences, Inc.
ANIX
LISTED
NASDAQ
Anixa Biosciences Announces Issuance of Chinese Patent Covering Breast Cancer Vaccine Technology
News Preview
Expands global intellectual property coverage in markets with high breast cancer incidence
New patent will provide IP protection of Breast Cancer Vaccine in China into 2040
SAN JOSE, Calif., Oct. 20, 2025 /PRNe...
Themefolio
Profiler
Peergroup
© BusinessWire
20.10.2025
ISIN: US74765K1051
Quantum-Si Inc
QSI
LISTED
NASDAQ
Quantum-Si to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
News Preview
Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule detection, today announced that it will be participating in the CG MedTech, Diagnostics and Digital Health & Services Forum taking place Thursday, November 20, 2025 at the Westin NY G...
Themefolio
Profiler
Peergroup
© BusinessWire
20.10.2025
ISIN: US1598641074
Charles River Laboratories International Inc
CRL
LISTED
NYSE
Charles River and X-Chem Announce Strategic Collaboration to Enhance Hit Identification Capabilities
News Preview
Charles River Laboratories International, Inc. (NYSE:CRL) today announced a strategic collaboration with X-Chem, Inc., the pioneer in DNA-encoded library (DEL) technology and a data-driven drug discovery company, to enhance its hit identification (Hit ID) capabilities and accelerate the discovery of novel therapeutics. This partnership enables Cha...
Themefolio
Profiler
Peergroup
© BusinessWire
20.10.2025
ISIN: US81663L2007
GeneDx Holdings Corp
WGS
LISTED
NASDAQ
GeneDx Granted FDA Breakthrough Device Designation for its ExomeDx™ and GenomeDx™ Testing
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its whole genome and exome tests associated with causes of life-threatening diseases or genetic disorders to aid in diagnosis of symptomatic...
Themefolio
Profiler
Peergroup
© BusinessWire
20.10.2025
ISIN: US45781M1018
Innoviva Inc
INVA
LISTED
NASDAQ
Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025
News Preview
Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (NASDAQ: INVA), will share new data on zoliflodacin during the Infectious Disease Society of America’s IDWeek 2025 annual meeting in Atlanta, GA, October 19-22, 2025. Zoliflodacin is a first-in-class oral antibiotic being developed for the treatment of uncomplicated gonorrhea. Three s...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.10.2025
ISIN: CA72706K1012
Planet 13 Holdings Inc.
PLTH
LISTED
CSE
Planet 13 Continues Florida Expansion, Opening its New Pace Dispensary on a Busy Retail Corridor near Pensacola
News Preview
Las Vegas, NV, Oct. 20, 2025 (GLOBE NEWSWIRE) -- – Planet 13 Holdings Inc. (CSE: PLTH) (OTCQX: PLNH) (“Planet 13” or the “Company”), a leading vertically-integrated multi-state cannabis company, today announced the opening of its newest Florida dispensary in Pace at 4612 School Lane just off busy US Highway 90....
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: US00287Y1091
AbbVie Inc
ABBV
LISTED
EURONEXT
RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor
News Preview
Upadacitinib demonstrated superiority versus adalimumab
for
primary endpoint of achieving low disease activity (DAS28-CRP≤3.2) and ranked secondary endpoint of remission (DAS28-CRP<2.6) at week 121
SELECT-SWIT...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: US23918K1088
DaVita Inc
DVA
LISTED
NYSE
DaVita Leads the Way in Evaluating Middle Molecule Clearance with Two New Initiatives
News Preview
New U.S. data will offer first-of-its-kind evidence in patients with kidney failure
DENVER, Oct. 20, 2025 /PRNewswire/ -- DaVita today announced the launch of two groundbreaking initiatives aimed to deepen the medical community's understanding of middle-molecule removal and its...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: US04351N1063
Ascend Wellness Holdings, Inc
AAWH.U
LISTED
CSE
AWH to Hold Third Quarter 2025 Earnings Conference Call on Monday, November 10, 2025
News Preview
NEW YORK, Oct. 20, 2025 /CNW/ - Ascend Wellness Holdings, Inc. ("AWH", "Ascend" or the "Company") (CSE: AAWH.U) (OTCQX: AAWH), a multi-state, vertically integrated cannabis operator, today announced that it will hold a conference call on Monday, November 10, 2025, at 5:00 PM ET following the release of its third...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: US04351N1063
Ascend Wellness Holdings, Inc
AAWH.U
LISTED
CSE
AWH to Hold Third Quarter 2025 Earnings Conference Call on Monday, November 10, 2025
News Preview
NEW YORK, Oct. 20, 2025 /PRNewswire/ - Ascend Wellness Holdings, Inc. ("AWH", "Ascend" or the "Company") (CSE: AAWH.U) (OTCQX: AAWH), a multi-state, vertically integrated cannabis operator, today announced that it will hold a conference call on Monday, November 10, 2025, at 5:00 PM ET following the release of its...
Themefolio
Profiler
Peergroup
© BusinessWire
20.10.2025
ISIN: US8523123052
STAAR Surgical Co
STAA
LISTED
NASDAQ
STAAR Surgical Announces Preliminary Net Sales Results for Third Quarter 2025
News Preview
STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced preliminary net sales results for the third quarter ended September 26, 2025. STAAR is announcing its preliminary net sales results in advance of its quarterly earnings announ...
Themefolio
Profiler
Peergroup
© BusinessWire
20.10.2025
ISIN: US92790C1045
Viridian Therapeutics Inc
VRDN
LISTED
NASDAQ
Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million
News Preview
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potentially best-in-class medicines for serious and rare diseases, today announced it entered into a royalty financing agreement with DRI Healthcare Acquisitions LP (DRI) and accelerated its timelines for the submission of the...
Themefolio
Profiler
Peergroup
© BusinessWire
20.10.2025
ISIN: US86150R1077
Stoke Therapeutics Inc
STOK
LISTED
NASDAQ
Stoke Therapeutics Presents Two-Year Natural History Data from Patients with Autosomal Dominant Optic Atrophy (ADOA)
News Preview
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicines, today announced the presentation of two-year data from the FALCON study, a prospective natural history study in people with Autosomal Dominant Optic Atrophy (ADOA) (n=47). Results were pr...
Themefolio
Profiler
Peergroup
© Newsfile
20.10.2025
ISIN: CA74040N1069
Predictmedix AI Inc
PMED
LISTED
CSE
Predictmedix AI Announces Non-Brokered Private Placement
News Preview
Toronto, Ontario--(Newsfile Corp. - October 20, 2025) - Predictmedix AI Inc. (CSE: PMED) (OTC Pink: PMEDF) (FSE: 3QP0) ("Predictmedix" or the "Company"), an emerging leader in AI-powered health and safety technology, announces a proposed non brokered private placement. The Company intends to issue (the "Offering") of up to 18,000,000 units (each, a...
Themefolio
Profiler
Peergroup
© BusinessWire
20.10.2025
ISIN: US02157Q1094
Alto Neuroscience, Inc.
ANRO
LISTED
NYSE
Alto Neuroscience Announces $50 Million Private Placement Financing
News Preview
Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, announced today that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement financing (t...
Themefolio
Profiler
Peergroup
© BusinessWire
20.10.2025
ISIN: US02157Q1094
Alto Neuroscience, Inc.
ANRO
LISTED
NYSE
Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting
News Preview
Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, announced today that, following a successful outcome from a recent FDA meeting, it plans to accelerate the development of ALTO-207 for people with treatment resistant depr...
Themefolio
Profiler
Peergroup
© BusinessWire
20.10.2025
ISIN: US29251M1062
Enanta Pharmaceuticals Inc
ENTA
LISTED
NASDAQ
Enanta Pharmaceuticals Presents New Data for Zelicapavir, its N-Protein Inhibitor, and EDP-323, its L-Protein Inhibitor, Both in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025
News Preview
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that new data for zelicapavir, its oral, once-daily, N-protein inhibitor, and EDP-323, its oral, once-daily L-protein inhibitor, both in development fo...
Themefolio
Profiler
Peergroup
© BusinessWire
20.10.2025
ISIN: US3773221029
Glaukos Corp
GKOS
LISTED
NYSE
Glaukos Announces FDA Approval of Epioxa™
News Preview
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today the U.S. Food and Drug Administration (FDA) approved its Epioxa™ HD / Epioxa™ (“Epioxa”) New Drug Application (NDA). Epioxa is a groundbreak...
Themefolio
Profiler
Peergroup
© Newsfile
20.10.2025
ISIN: CA74141E1043
PreveCeutical Medical Inc.
PREV
LISTED
CSE
PreveCeutical Provides Update on Plan of Arrangement with BioGene Therapeutics Inc.
News Preview
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVancouver, British Columbia--(Newsfile Corp. - October 20, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its News Releases of September 4, 2...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.10.2025
ISIN: US98888T1079
ZimVie, Inc.
ZIMV
LISTED
NASDAQ
ZimVie Announces Completion of its Acquisition by ARCHIMED
News Preview
ZimVie Inc. Becomes Privately Held Company ZimVie Inc. Becomes Privately Held Company...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: CA39986R1064
Grown Rogue International Inc.
GRIN
LISTED
CSE
Grown Rogue to Report Third Quarter 2025 Financial Results and Host Conference Call on November 11, 2025
News Preview
MEDFORD, Ore., Oct. 20, 2025 /CNW/ - Grown Rogue International Inc. ("Grown Rogue" or the "Company") (CSE: GRIN) (OTC: GRUSF), a flower-forward cannabis company combining craft values with disciplined execution, will report its financial results for the third quarter ended September 30, 2025, on Tuesday, November...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: US0758871091
Becton Dickinson and Co
BDX
LISTED
NYSE
BD Launches New AI-enabled Solutions to Drive Connectivity Across Healthcare Settings
News Preview
FRANKLIN LAKES, N.J., Oct. 20, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a global leader in medical technology, introduces the BD Incada™ Connected Care Platform, a new scalable, AI-enabled, cloud-based platform that unifies BD device data into one intelligent ecosystem for the first ti...
Themefolio
Profiler
Peergroup
© BusinessWire
20.10.2025
ISIN: US86627T1088
Summit Therapeutics Inc
SMMT
LISTED
NASDAQ
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the third quarter ended September 30, 2025.
Planned BLA Submission for Ivonescimab in Q4 2025
Today, Summit announces that, based on the results of the HARMONi clinical trial, it plan...
Themefolio
Profiler
Peergroup
© BusinessWire
20.10.2025
ISIN: US58933Y1055
Merck & Co Inc
MRK
LISTED
NYSE
Merck Breaks Ground on $3 Billion Center of Excellence for Pharmaceutical Manufacturing in Elkton, Virginia
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the start of construction for a $3 billion, 400,000-square-foot pharmaceutical manufacturing facility at its Elkton, Virginia, site.
Merck’s investment in the Center of Excellence for Pharmaceutical Manufacturing is part of a more than $70 billion investment...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.10.2025
ISIN: US9032141049
Cogent Biosciences, Inc.
COGT
LISTED
NASDAQ
Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib
News Preview
WALTHAM, Mass. and BOULDER, Colo., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for bezuclastinib in NonAdva...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.10.2025
ISIN: US0044685008
Achieve Life Sciences, Inc.
ACHV
LISTED
NASDAQ
Achieve Life Sciences Appoints Erik Atkisson as Chief Legal Officer
News Preview
New life sciences executive brings more than 25 years of legal expertise spanning clinical and commercial stage biopharmaceutical companies New life sciences executive brings more than 25 years of legal expertise spanning clinical and commercial stage biopharmaceutical companies...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: US45166A1025
IDEAYA Biosciences Inc
IDYA
LISTED
NASDAQ
IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma in a Proffered Paper Oral Presentation at ESMO 2025
News Preview
83% (78/94) of patients demonstrated ocular tumor shrinkage, with 54% (51/94) achieving ≥20% tumor shrinkage
57% (24/42) eye preservation rate in enucleation (EN) recommended patients, which increased to 95% (19/20) in patients achieving ≥20% ocular tumor shrinkage
70% (26/37)...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: US3847471014
Grail, Inc.
GRAL
LISTED
NASDAQ
GRAIL, Inc. Announces $325.0 Million Private Placement Financing
News Preview
MENLO PARK, Calif., Oct. 20, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approxim...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.10.2025
ISIN: US00972D1054
Akebia Therapeutics Inc
AKBA
LISTED
NASDAQ
Akebia Therapeutics Announces Five Presentations at ASN Kidney Week 2025
News Preview
Presentations Detail Ongoing Vafseo® (Vadadustat) Real-World Studies and Explore Insights Regarding Clinical Benefits and Dosing of Vafseo Presentations Detail Ongoing Vafseo® (Vadadustat) Real-World Studies and Explore Insights Regarding Clinical Benefits and Dosing of Vafseo...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.10.2025
ISIN: AU000000IMM6
Immutep Ltd
IMM
LISTED
ASX
Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented at ESMO Congress 2025
News Preview
SYDNEY, AUSTRALIA, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces positive data from the EFTISARC-NEO Phase II trial were shared in a Proffered Paper oral presentation by Katarzyna Kozak, M.D., Ph....
Themefolio
Profiler
Peergroup
© BusinessWire
20.10.2025
ISIN: US3596641098
Fulgent Genetics Inc
FLGT
LISTED
NASDAQ
Fulgent Shares Preliminary Data from Poster Presentation at ESMO 2025 Conference
News Preview
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced preliminary clinical data as of September 25, 2025, the preliminary data cutoff from its ongoing phase 2 clinical trial investigating FID-007 in...
Themefolio
Profiler
Peergroup
© BusinessWire
20.10.2025
ISIN: US07725L1026
BeOne Medicines Ltd.
ONC
LISTED
NASDAQ
BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025
News Preview
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of data from two pivotal Phase 3 trials – RATIONALE-307 and 312 – offering new evidence of the benefits of its PD-1 inhibitor, TEVIMBRA® (tislelizumab), at the European Society of Medical Oncology 2025 Congress (ESMO 2025) in B...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.10.2025
ISIN: US71722W1071
Phathom Pharmaceuticals Inc
PHAT
LISTED
NASDAQ
Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025
News Preview
FLORHAM PARK, N.J., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, October 30, 2025, to report its third quarter 2025 fi...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.10.2025
ISIN: US15713L1098
CervoMed Inc.
CRVO
LISTED
NASDAQ
CervoMed to Present at the Emerging Growth Conference
News Preview
BOSTON, Oct. 20, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that Matthew Winton, Ph.D., Chief Commercial and Business Officer, will present at the Emerging Growth Conference, being held virtually on...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: US3847471014
Grail, Inc.
GRAL
LISTED
NASDAQ
GRAIL and University of Oxford to Present Long-Term Data From the SYMPLIFY Study Evaluating the Galleri® Multi-Cancer Early Detection Test in Symptomatic Individuals at the Early Detection of Cancer Conference (EDCC)
News Preview
One-Third of Participants Initially Believed to Have a False-Positive Result Were Later Diagnosed With Cancer During Follow Up
Updated Positive Predictive Value of Galleri in This Symptomatic Populati...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: US45166A1025
IDEAYA Biosciences Inc
IDYA
LISTED
NASDAQ
IDEAYA Biosciences Reports Positive Median Overall Survival Data from Phase 2 Trial of the Darovasertib and Crizotinib Combination in First-line Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress
News Preview
Combination demonstrated median overall survival (OS) of 21.1 months, compared to reported historical mOS of approximately 12 months in published meta-analysis of metastatic uveal melanoma in the first-line setting
Median progression free survival (PFS) of 7.0 months
Confirmed...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.10.2025
ISIN: US21900C3088
CorMedix Inc
CRMD
LISTED
NASDAQ
CorMedix Inc. Announces Preliminary Third Quarter 2025 Results and Raises 2025 Net Revenue Guidance
News Preview
‒ Q3 2025 Unaudited Pro Forma Net Revenue of more than $125 million ‒...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.10.2025
ISIN: US02155H1014
Altimmune, Inc.
ALT
LISTED
NASDAQ
Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025
News Preview
Oral presentation to highlight 24-week efficacy and safety data...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.10.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Sanofi’s Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program
News Preview
Sanofi’s Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.10.2025
ISIN: US34965KAA51
Fortrea Holdings Inc
FTRE
LISTED
NASDAQ
Fortrea Announces Tender Offer for up to $75,744,000 Aggregate Purchase Price of Outstanding Debt
News Preview
DURHAM, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced that it has commenced a debt tender offer (the “Tender Offer”) to purchase for cash up to $75,744,000 (the “Maximum Amount”) in aggregate purchase price of the Company’s outstanding 7.500...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.10.2025
ISIN: US03753U1060
Apellis Pharmaceuticals Inc
APLS
LISTED
NASDAQ
New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week
News Preview
WALTHAM, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced new data from the open-label period of the Phase 3 VALIANT study that reinforce the robust and sustained efficacy of EMPAVELI® (pegcetacoplan), a C3 inhibitor, in patients with C3 glomerulopathy (C3G) and primary immune complex membranop...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.10.2025
ISIN: US76029N1063
Replimune Group Inc
REPL
LISTED
NASDAQ
Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma
News Preview
Prescription Drug User Fee Act (PDUFA) target action date set for April 10, 2026 Prescription Drug User Fee Act (PDUFA) target action date set for April 10, 2026...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.10.2025
ISIN: CA17104U1021
Christina Lake Cannabis Corp
CLC
LISTED
CSE
Christina Lake Cannabis Announces Credit Facility and Lease Agreement
News Preview
Christina Lake Cannabis announces $1.5M secured credit facility and 18-month equipment lease...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
